CN112638905A - 作为rip2激酶抑制剂的喹唑啉类衍生物 - Google Patents

作为rip2激酶抑制剂的喹唑啉类衍生物 Download PDF

Info

Publication number
CN112638905A
CN112638905A CN201980056903.2A CN201980056903A CN112638905A CN 112638905 A CN112638905 A CN 112638905A CN 201980056903 A CN201980056903 A CN 201980056903A CN 112638905 A CN112638905 A CN 112638905A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
optical isomer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980056903.2A
Other languages
English (en)
Inventor
牟剑锋
吴松亮
贺海鹰
杨亚讯
张红进
张臣
龚珍
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medshine Discovery Inc
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN112638905A publication Critical patent/CN112638905A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings

Abstract

公开了一类喹唑啉类衍生物，具体公开式(Ⅰ)所示化合物及其药学上可接受的盐及其在制备RIP2激酶抑制剂的应用。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980056903.2A 2018-08-28 2019-08-28 作为rip2激酶抑制剂的喹唑啉类衍生物 Pending CN112638905A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810989839 2018-08-28
CN2018109898390 2018-08-28
CN2019101228253 2019-02-19
CN201910122825 2019-02-19
PCT/CN2019/102999 WO2020043122A1 (zh) 2018-08-28 2019-08-28 作为rip2激酶抑制剂的喹唑啉类衍生物

Publications (1)

Publication Number Publication Date
CN112638905A true CN112638905A (zh) 2021-04-09

Family

ID=69642897

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056903.2A Pending CN112638905A (zh) 2018-08-28 2019-08-28 作为rip2激酶抑制剂的喹唑啉类衍生物

Country Status (2)

Country Link
CN (1) CN112638905A (zh)
WO (1) WO2020043122A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058267A1 (en) * 2002-12-23 2004-07-15 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
WO2013025958A1 (en) * 2011-08-18 2013-02-21 Glaxo Group Limited Amino quinazolines as kinase inhibitors
WO2014043446A1 (en) * 2012-09-13 2014-03-20 Glaxosmithkline Llc Prodrugs of amino quinazoline kinase inhibitor
WO2014128622A1 (en) * 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
WO2016172134A2 (en) * 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2017046036A1 (en) * 2015-09-14 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Compounds for the modulation of rip2 kinase activity
WO2017182418A1 (en) * 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058267A1 (en) * 2002-12-23 2004-07-15 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
WO2013025958A1 (en) * 2011-08-18 2013-02-21 Glaxo Group Limited Amino quinazolines as kinase inhibitors
WO2014043446A1 (en) * 2012-09-13 2014-03-20 Glaxosmithkline Llc Prodrugs of amino quinazoline kinase inhibitor
WO2014128622A1 (en) * 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
WO2016172134A2 (en) * 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2017046036A1 (en) * 2015-09-14 2017-03-23 Glaxosmithkline Intellectual Property Development Limited Compounds for the modulation of rip2 kinase activity
WO2017182418A1 (en) * 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors

Also Published As

Publication number Publication date
WO2020043122A1 (zh) 2020-03-05

Similar Documents

Publication Publication Date Title
CN105555782B (zh) 喹唑啉衍生物及其制备方法
JP6267806B2 (ja) ２，４−二置換ベンゼン−１，５−ジアミン誘導体およびその使用ならびにそれから製造される医薬組成物および薬用組成物
JP2023523640A (ja) ベンゾチアゾリルビアリール系化合物、その調製方法及び使用
CN109071448A (zh) Ask1抑制剂及其制备方法和应用
TWI723131B (zh) 6‐雜環基‐4‐嗎啉‐4‐芳基吡啶‐2‐酮化合物
TWI641602B (zh) 單環吡啶衍生物
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN114867720A (zh) 杂芳基类衍生物及其制备方法和用途
NO169070B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive n-heterosyklisk-n-(4-piperidyl)-amider
JP7162741B2 (ja) 新規なヘテロサイクリックアミン誘導体およびこれを含む薬学組成物
TW202115035A (zh) 雜環醯胺類化合物及其製備方法和應用
CN111683928A (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN109661395A (zh) Pde4抑制剂
CN116888108B (zh) 新型egfr降解剂
CN105732602A (zh) 作为ns4b抑制剂的苯并呋喃类似物
JP2022511236A (ja) 置換キナゾリノン誘導体、及びｍＧｌｕＲ４のポジティブアロステリック調節剤としてのその使用
EA037876B1 (ru) Соединение в виде аминозамещенного шестичленного гетероциклического кольца с гетероатомом азота, его получение и использование
CN112638905A (zh) 作为rip2激酶抑制剂的喹唑啉类衍生物
CN114845996A (zh) 一种含苯环的化合物及其应用
CA3235504A1 (en) Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
CN113214240B (zh) 作为p2x3受体拮抗剂的n-甲酰胺基吡唑啉类衍生物及应用
CN112538084B (zh) 新颖的kras g12c蛋白抑制剂及其制备方法和用途
WO2021121390A1 (zh) 杂环化合物及其药物组合物、制备方法、中间体和应用
KR20240019071A (ko) N2-페닐피리미딘-2,4-디아민 화합물, 및 그 제조 방법 및 사용 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210409